USA-based King Pharmaceuticals reported a third-quarter 2007 loss of $40.5 million, or $0.17 per share, down from the $90.4 million profit it recorded in the comparable period last year.
King said that the decline was due to a $264.0 million charge related to restructuring and impairment activities-following a ruling that its patent for the hypertension drug Altace (ramipril) was invalid (Marketletter September 27). The firm added that it expects to report a $50.0 million restructuring charge in the next quarter.
On a more positive note, revenues for the period were up 11% to $544.9 million, beating the forecast of analysts polled by Thomson Financial who had predicted $528.4 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze